Table 1.
EU-COVAT-1-AGED intervention in Part B – 4th vaccination doseb
| Cohort | Vaccination prior to study entry | Arm | Study intervention: 4th vaccination dosea |
|---|---|---|---|
| Cohort 4 | BNT162b2 + BNT162b2 + BNT162b2 | 7 | BNT162b2 |
| 8 | mRNA-1273 | ||
| Cohort 5 | BNT162b2 + BNT162b2 + mRNA-1273 | 9 | BNT162b2 |
| 10 | mRNA-1273 | ||
| Cohort 6 | mRNA-1273 + mRNA-1273 + mRNA-1273 | 11 | BNT162b2 |
| 12 | mRNA-1273 | ||
| Cohort 7 | mRNA-1273 + mRNA-1273 + BNT162b2 | 13 | BNT162b2 |
| 14 | mRNA-1273 | ||
| Cohort 8 | ChAdOx-1-S + ChAdOx-1-S + BNT162b2 | 15 | BNT162b2 |
| 16 | mRNA-1273 | ||
| Cohort 9 | ChAdOx-1-S + ChAdOx-1-S + mRNA-1273 | 17 | BNT162b2 |
| 18 | mRNA-1273 |
aAdministered at least 1 month after the 3rd pre-study vaccination
bFor intervention in Part A (3rd vaccination dose) see Additional file 1